-
1Academic Journal
Συγγραφείς: Galembikova A.R., Dunaev P.D., Ivoilova T.V., Gilyazova A.I., Galyautdinova A.E., Mikheeva E.G., Zykova S.S., Igidov N.M., Kopnin P.B., Boichuk S.V.
Συνεισφορές: The study was carried out with the support of the Russian Science Foundation (RSF) (grant No. 20-15-00001) and was performed as a part of Russia Strategic Academic Leadership Program (“Priority-2030”) of Kazan (Volga Region) Federal University, Исследование выполнено при поддержке Российского научного фонда (грант № 20-15-00001) и проведено в рамках Программы стратегического академического лидерства ФГАОУ ВО «Казанский (Приволжский) федеральный университет» («Приоритет-2030»)
Πηγή: Advances in Molecular Oncology; Vol 11, No 2 (2024); 130-146 ; Успехи молекулярной онкологии; Vol 11, No 2 (2024); 130-146 ; 2413-3787 ; 2313-805X
Θεματικοί όροι: microtubules, tubulin depolymerization, cell cycle, apoptosis, mitotic catastrophe, multidrug resistance, triple-negative breast cancer, gastrointestinal stromal tumor, osteosarcoma, colorectal adenocarcinoma, ethyl-pyrrole-carboxyls, pyrrole-carboxamides, paclitaxel, vinblastine, doxorubicin, микротрубочки, деполимеризация тубулина, клеточный цикл, апоптоз, митотическая катастрофа, множественная лекарственная устойчивость, трижды негативный рак молочной железы, гастроинтестинальная стромальная опухоль, остеосаркома, колоректальная аденокарцинома, этил-пиррол-карбоксилы, пиррол-карбоксамиды, паклитаксел, винбластин, доксорубицин
Περιγραφή αρχείου: application/pdf
Relation: https://umo.abvpress.ru/jour/article/view/683/355; https://umo.abvpress.ru/jour/article/view/683
-
2Academic Journal
Συγγραφείς: A. R. Galembikova, P. D. Dunaev, T. V. Ivoilova, A. I. Gilyazova, A. E. Galyautdinova, E. G. Mikheeva, S. S. Zykova, N. M. Igidov, P. B. Kopnin, S. V. Boichuk, А. Р. Галембикова, П. Д. Дунаев, Т. В. Ивойлова, А. И. Гилязова, А. Э. Галяутдинова, Е. Г. Михеева, С. С. Зыкова, Н. М. Игидов, П. Б. Копнин, С. В. Бойчук
Συνεισφορές: The study was carried out with the support of the Russian Science Foundation (RSF) (grant No. 20-15-00001) and was performed as a part of Russia Strategic Academic Leadership Program (“Priority-2030”) of Kazan (Volga Region) Federal University, Исследование выполнено при поддержке Российского научного фонда (грант № 20-15-00001) и проведено в рамках Программы стратегического академического лидерства ФГАОУ ВО «Казанский (Приволжский) федеральный университет» («Приоритет-2030»)
Πηγή: Advances in Molecular Oncology; Том 11, № 2 (2024); 130-146 ; Успехи молекулярной онкологии; Том 11, № 2 (2024); 130-146 ; 2413-3787 ; 2313-805X
Θεματικοί όροι: доксорубицин, tubulin depolymerization, cell cycle, apoptosis, mitotic catastrophe, multidrug resistance, triple-negative breast cancer, gastrointestinal stromal tumor, osteosarcoma, colorectal adenocarcinoma, ethyl-pyrrole-carboxyls, pyrrole-carboxamides, paclitaxel, vinblastine, doxorubicin, деполимеризация тубулина, клеточный цикл, апоптоз, митотическая катастрофа, множественная лекарственная устойчивость, трижды негативный рак молочной железы, гастроинтестинальная стромальная опухоль, остеосаркома, колоректальная аденокарцинома, этил-пиррол-карбоксилы, пиррол-карбоксамиды, паклитаксел, винбластин
Περιγραφή αρχείου: application/pdf
Relation: https://umo.abvpress.ru/jour/article/view/683/355; Bhardwaj V., Gumber D., Abbot V. et al. Pyrrole: a resourceful small molecule in key medicinal hetero-aromatics. RSC Adv 2015;5:15233–66. DOI:10.1039/C4RA15710A; DeSimone R.W., Currie K.S., Mitchell S.A. et al. Privileged structures: applications in drug discovery. Comb Chem High Throughput Screen 2004;7(5):473–93. DOI:10.2174/1386207043328544; Duarte C.D., Barreiro E.J., Fraga C.A.M. Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini-Rev Med Chem 2007;7(11):1108–19. DOI:10.2174/138955707782331722; Li Petri G., Spanò V., Spatola R. et al. Bioactive pyrrole-based compounds with target selectivity. Eur J Med Chem 2020;208:112783. DOI:10.1016/j.ejmech.2020.112783; Walsh C.T., Garneau-Tsodikova S., Howard-Jones A.R. Biological formation of pyrroles: Nature’s logic and enzymatic machinery. Nat Prod Rep 2006;23:517–31. DOI:10.1039/b605245m; Ahmad S., Alam O., Naim M.J. et al. Pyrrole: An insight into recent pharmacological advances with structure activity relationship. Eur J Med Chem 2018;157:527–61. DOI:10.1016/j.ejmech.2018.08.002; Bianco M.C.A.D., Marinho D.I.L.F., Hoelz L.V.B. et al. Pyrroles as privileged scaffolds in the search for new potential HIV inhibitors. Pharmaceuticals 2021;14(9):893. DOI:10.3390/ph14090893; La Regina G., Bai R., Coluccia A. et al. New pyrrole derivatives with potent tubulin polymerization inhibiting activity as anticancer agents including hedgehog-dependent cancer. J Med Chem 2014;57:6531–52. DOI:10.1021/jm500561a; Jadala C., Prasad B., Prasanthi A.V.G. et al. Transition metal-free one-pot synthesis of substituted pyrroles by employing aza-Wittig reaction. RSC Adv 2019;9:30659–65. DOI:10.1039/C9RA06778G; Tang S., Zhou Z., Jiang Z. et al. Indole-based tubulin inhibitors: binding modes and sars investigations. Molecules 2022;27(5):1587. DOI:10.3390/molecules27051587; Romagnoli R., Oliva P., Salvador M.K. et al. A facile synthesis of diaryl pyrroles led to the discovery of potent colchicine site antimitotic agents. Eur J Med Chem 2021;214:113229. DOI:10.1016/j.ejmech.2021.113229; Sun J., Chen L., Liu C. et al. Synthesis and biological evaluations of 1,2-diaryl pyrroles as analogues of combretastatin A-4. Chem Biol Drug Des 2015;86(6):1541–7. DOI:10.1111/cbdd.12617; Ma Z., Ma Z., Zhang D. Synthesis of multi-substituted pyrrole derivatives through [3+2] cycloaddition with tosylmethyl isocyanides (TosMICs) and electron-deficient compounds. Molecules 2018;23(10):2666. DOI:10.3390/molecules23102666; Mowery P., Mejia F.B., Franceschi C.L. et al. Synthesis and evaluation of the anti-proliferative activity of diaryl-3-pyrrolin-2-ones and fused analogs. Bioorganic Med Chem Lett 2017;27(2):191–5. DOI:10.1016/j.bmcl.2016.11.076; Boichuk S., Galembikova A., Syuzov K. et al. The design, synthesis, and biological activities of pyrrole-based carboxamides: the novel tubulin inhibitors targeting the colchicine-binding site. Molecules 2021;26(19):5780. DOI:10.3390/molecules26195780; Findeisen P., Mühlhausen S., Dempewolf S. et al. Six subgroups and extensive recent duplications characterize the evolution of the eukaryotic tubulin protein family. Genome Biol Evol 2014;6(9):2274–88. DOI:10.1093/gbe/evu187; Avila J. Microtubule functions. Life Sci 1992;50(5):327–34. DOI:10.1016/0024-3205(92)90433-P; Vukušić K., Buđa R., Tolić I.M. Force-generating mechanisms of anaphase in human cells. J Cell Sci 2019;132(18):jcs231985. DOI:10.1242/jcs.231985; de Forges H., Bouissou A., Perez F. Interplay between microtubule dynamics and intracellular organization. Int J Biochem Cell Biol 2012;44(2):266–74. DOI:10.1016/j.biocel.2011.11.009; Bonifacino J.S., Neefjes J. Moving and positioning the endolysosomal system. Curr Opin Cell Biol 2017;47:266–74. DOI:10.1016/j.ceb.2017.01.008; Wood K.W., Cornwell W.D., Jackson J.R. Past and future of the mitotic spindle as an oncology target. Curr Opin Pharmacol 2001;1(4):370–7. DOI:10.1016/s1471-4892(01)00064-9; von Hoff D.D. The taxoids: Same roots, different drugs. Semin Oncol 1997;24(13):S13-3–10.; Bollag D.M., McQueney P.A., Zhu J. et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55(11):2325–33.; Gigant B., Wang C., Ravelli R.B.G. et al. Structural basis for the regulation of tubulin by vinblastine. Nature 2005;435(7041):519–22. DOI:10.1038/nature03566; Hastie S.B. Interactions of colchicine with tubulin. Pharmacol Ther 1991;51(3):377–401. DOI:10.1016/0163-7258(91)90067-V; Mooberry S.L., Tien G., Hernandez A.H. et al. Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res 1999;59(3):653–60.; Hamel E. Natural products which interact with tubulin in the vinca domain: Maytansine, rhizoxin, phomopsin a, dolastatins 10 and 15 and halichondrin B. Pharmacol Ther 1992;55(1):31–51. DOI:10.1016/0163-7258(92)90028-X; Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nat Cancer 2004;4(4):253–65. DOI:10.1038/nrc1317; Stanton R.A., Gernert K.M., Nettles J.H. et al. Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev 2011;31(3):443–81. DOI:10.1002/med.20242; Ravelli R.B., Gigant G., Curmi B. et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004;428(6979):198–202. DOI:10.1038/nature02393; Yang J., Wang Y., Wang T. et al. Pironetin reacts covalently with cysteine-316 of α-tubulin to destabilize microtubule. Nat Commun 2016;7:12103. DOI:10.1038/ncomms12103; Prota A.E., Setter J., Waight A.B. et al. Pironetin binds covalently to αCys316 and perturbs a major loop and helix of α-tubulin to inhibit microtubule formation. J Mol Biol 2016;428(15):2981–8. DOI:10.1016/j.jmb.2016.06.023; Steinmetz M.O., Prota A.E. Microtubule-targeting agents: strategies to hijack the cytoskeleton. Trends Cell Biol 2018;28(10):776–92. DOI:10.1016/j.tcb.2018.05.001; Fanale D., Bronte G., Passiglia F. et al. Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? Anal Cell Pathol (Amst) 2015;2015:690916. DOI:10.1155/2015/690916; West L.M., Northcote P.T., Battershill C.N. Peloruside A. A potent cytotoxic macrolide isolated from the New Zealand marine sponge Mycale sp. J Org Chem 2000;65(2):445–9. DOI:10.1021/jo991296y; Prota A.E., Bargsten K., Northcote P.T. et al. Structural basis of microtubule stabilization by laulimalide and peloruside A. Angew Chem Int Ed Engl 2014;53(6):1621–5. DOI:10.1002/anie.201307749.; Chaplin D.J., Hill S.A. The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol 2002;54(5):1491–6. DOI:10.1016/S0360-3016(02)03924-X; Siemann D.W., Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res 2008;28(4 B):2027–31.; Lindamulage I.K., Vu H.-Y., Karthikeyan C. et al. Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function. Sci Rep 2017;7(1):10298. DOI:10.1038/s41598-017-10972-0; Gupta S., Banerjee M., Poddar A. et al. Biphasic kinetics of the colchicine−tubulin interaction: role of amino acids surrounding the A ring of bound colchicine molecule. Biochemistry 2005;44(30):10181–8. DOI:10.1021/bi050599l; McLoughlin E.C., O’Boyle N.M. Colchicine-binding site inhibitors from chemistry to clinic : a review. Pharmaceuticals 2020;13(1):8. DOI:10.3390/ph13010008; Arnst K.E., Banerjee S., Chen H. et al. Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy. Med Res Rev 2019;39(4):1398–426. DOI:10.1002/med.21568; Зыкова С.С., Бойчук С.В., Галембикова А.Р. и др. 3-гидрокси-1,5-диарил-4-пивалоил-2,5-дигидро-2-пирролоны нарушают процессы митоза и индуцируют гибель опухолевых клеток in vitro. Цитология 2014;56:439–42. – Zykova S.S., Boychuk S.V., Galimbekova A.R. et al. 3-hydroxy-1,5-diaryl-4-pivaloyl-2,5-dihydro-2-pyrrolone disrupt the processes of mitosis and induce the death of tumor cells in vitro. Citologiya = Cytology 2014;56:439–42. (In Russ.).; Boichuk S., Galembikova A., Zykova S. et al. Ethyl-2-amino-pyrrole-3-carboxylates are novel potent anticancer agents that affect tubulin polymerization, induce G2/M cell-cycle arrest, and effectively inhibit soft tissue cancer cell growth in vitro. Anti-Cancer Drugs 2016;27(7):620–34. DOI:10.1097/CAD.0000000000000372; Boichuk S., Galembikova A., Dunaev P. et al. Ethyl-2-amino-pyrrole-3-carboxylates are active against imatinib-resistant gastrointestinal stromal tumors in vitro and in vivo. Anti-Cancer Drugs 2019;30(5):475–84. DOI:10.1097/CAD.0000000000000753; Boichuk S., Bikinieva F., Mustafin I. et al. 2-Amino-pyrrole-carboxylate attenuates homology-mediated DNA repair and sensitizes cancer cells to doxorubicin. Biochemistry (Mosc) 2022;87(5):391–9. DOI:10.1134/S0006297922050017; Boichuk S., Syuzov K., Bikinieva F. et al. Computational-based discovery of the anti-cancer activities of pyrrole-based compounds targeting the colchicine-binding site of tubulin. Molecules 2022;27(9):2873. DOI:10.3390/molecules27092873; Boichuk S., Galembikova A., Bikinieva F. et al. 2-APCAs, the novel microtubule targeting agents active against distinct cancer cell lines. Molecules 2021;26(3):616. DOI:10.3390/molecules26030616; Галембикова А.Р., Дунаев П.Д., Бикиниева Ф.Ф. и др. Механизмы цитотоксической активности пиррол-карбоксамидов в отношении опухолевых клеточных сублиний с множественной лекарственной устойчивостью. Успехи молекулярной онкологии 2023;10(3):59–71. DOI:10.17650/2313-805X-2023-10-3-59-71; Carta D., Bortolozzi R., Sturlese M. et al. Synthesis, structure-activity relationships and biological evaluation of 7-phenyl-pyrroloquinolinone 3-amide derivatives as potent antimitotic agents. Eur J Med Chem 2017;127:643–60. DOI:10.1016/j.ejmech.2016.10.026; Brindisi M., Ulivieri C., Alfano G. et al. Structure-activity relationships, biological evaluation and structural studies of novel pyrrolonaphthoxazepines as antitumor agents. Eur J Med Chem 2019;162:290–320. DOI:10.1016/j.ejmech.2018.11.004; Zykova S.S., Galembikova A.R., Ramazanov B.R. et al. Synthesis and cytotoxic activity of ethyl 2-amino-1-benzamido-4-oxo-5-(2-oxo-2-arylethylidene)-4,5-dihydro-1H-pyrrole-3-carboxylates. Pharm Chem J 2016;49(12):817–20. DOI:10.1007/s11094-016-1378-1; Zykova S.S., Igidov N.M., Zakhmatov A.V. et al. Synthesis and biological activity of 2-amino-1-aryl-5-(3,3-dimethyl-2-oxobutylidene)-4-oxo-n-(thiazol-5-yl)-4,5-dihydro-1H-pyrrole-3-carboxamides. Pharm Chem J 2018;52(3):198–204.; Zykova S.S., Kizimova I.A., Syutkina A.I. et al. Synthesis and cytostatic activity of (e)-ethyl-2-amino-5-(3,3-dimethyl-4-oxobutyliden)-4-oxo-1- (2-phenylaminobenzamido)-4,5-dihydro-1hpyrrol-3-carboxylate. Pharm Chem J 2020;53:895–8. DOI:10.1007/s11094-020-02096-z; Boichuk S., Galembikova A., Sitenkov A. et al. Establishment and characterization of a triple negative basal-like breast cancer cell line with multi-drug resistance. Oncol Lett 2017;14(4):5039–45. DOI:10.3892/ol.2017.6795; Boichuk S., Bikinieva F., Valeeva E. et al. Establishment and characterization of multi-drug resistant p53-negative osteosarcoma SaOS-2 subline. Diagnostics (Basel) 2023;13(16):2646. DOI:10.3390/diagnostics13162646; Хуснутдинов Р.Р., Галембикова А.Р., Бойчук С.В. Получение клона клеток гастроинтестинальной стромальной опухоли с признаками множественной лекарственной устойчивости и оценка его свойств. Современные технологии в медицине 2016;8(4):36–41. DOI:10.17691/stm2016.8.4.05; Taguchi T., Sonobe H., Toyonaga S. et al. Conventionaland molecular cytogenetic characterization of a newhuman cell line, GIST-T1, established from gastrointestinal stromal tumor. Lab Invest 2002;82(5):663–5. DOI:10.1038/labinvest.3780461; Wittmann C., Sivchenko A.S., Bacher F. et al. Inhibition of microtubule dynamics in cancer cells by indole-modified latonduine derivatives and their metal complexes. Inorg Chem 2022;61(3):1456–70. DOI:10.1021/acs.inorgchem.1c03154; Boichuk S., Dunaev P., Mustafin I. et al. Infigratinib (BGJ 398), a pan-FGFR inhibitor, targets P-glycoprotein and increases chemotherapeutic-induced mortality of multidrug-resistant tumor cells. Biomedicines 2022;10(3):601. DOI:10.3390/biomedicines10030601; Marupudi N.I., Han J.E., Li K.W. et al. Paclitaxel : a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf 2007;6(5):609–21. DOI:10.1517/14740338.6.5.609; Young J.A., Howell S.B., Green M.R. Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine. Cancer Chemother Pharmacol 1984;12(1):43–5. DOI:10.1007/BF00255908; Mora E., Smith E.M., Donohoe C. et al. Vincristine-induced peripheral neuropathy in pediatric cancer patients. Am J Cancer Res 2016;6(11):2416–30.; Abu Samaan T.M., Samec M., Liskova A. et al. Paclitaxel’s mechanistic and clinical effects on breast cancer. Biomolecules. 2019;9(12):789. DOI:10.3390/biom9120789; Hashemi M., Zandieh M.A., Talebi Y. et al. Paclitaxel and docetaxel resistance in prostate cancer: molecular mechanisms and possible therapeutic strategies. Biomed Pharmacother 2023;160:114392. DOI:10.1016/j.biopha.2023.114392; Zhang Y., Yang S.H., Guo X.L. New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer. Biomed Pharmacother 2017;96:659–66. DOI:10.1016/j.biopha.2017.10.041; Toledo B., González-Titos A., Hernández-Camarero P. et al. A brief review on chemoresistance; targeting cancer stem cells as an alternative approach. Int J Mol Sci 2023;24(5):4487. DOI:10.3390/ijms24054487; Distefano M., Scambia G., Ferlini C. et al. Antitumor activity of paclitaxel (taxol) analogues on MDR-positive human cancer cells. Anticancer Drug Des 1998;13(5):489–99.; Liu J., Yang X., Gao S. et al. DDX11-AS1 modulates DNA damage repair to enhance paclitaxel resistance of lung adenocarcinoma cells. Pharmacogenomics 2023;24(3):163–72. DOI:10.2217/pgs-2022-0121; Kavallaris M., Kuo D.Y., Burkhart C.A. et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Investig 1997;100(5): 1282–93. DOI:10.1172/JCI119642; Poruchynsky M.S., Giannakakou P., Ward Y. et al. Accompanying protein alterations in malignant cells with a microtubule-polymerizing drug-resistance phenotype and a primary resistance mechanism. Biochem Pharmacol 2001;62(11):1469–80. DOI:10.1016/s0006-2952(01)00804-8; Houghton J.A., Houghton P.J., Hazelton B.J. et al. In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered beta-tubulins. Cancer Res 1985;45(6):2706–12.; Stengel C., Newman S.P., Leese M.P. et al. Class III β-tubulin expression and in vitro resistance to microtubule targeting agents. Br J Cancer 2009;102:316–24. DOI:10.1038/sj.bjc.6605489; Rodríguez-Antona C. Pharmacogenomics of paclitaxel. Pharmacogenomics 2010;11(5):621–3. DOI:10.2217/pgs.10.32; Ezrahi S., Aserin A., Garti N. Basic principles of drug delivery systems – the case of paclitaxel. Adv Colloid Interface Sci 2019;263:95–130. DOI:10.1016/j.cis.2018.11.004; Tuy H.D., Shiomi H., Mukaisho K.I. et al. ABCG2 expression in colorectal adenocarcinomas may predict resistance to irinotecan. Oncol Lett 2016;12(4):2752–60. DOI:10.3892/ol.2016.4937; Mooberry S.L., Weiderhold K.N., Dakshanamurthy S. et al. Identification and characterization of a new tubulin-binding tetrasubstituted brominated pyrrole. Mol Pharmacol 2007;72(1):132–40. DOI:10.1124/mol.107.034876; https://umo.abvpress.ru/jour/article/view/683